These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 24992083

  • 1. Influence of the nonergot dopamine agonist piribedil on vigilance in patients With Parkinson Disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole.
    Eggert K, Öhlwein C, Kassubek J, Wolz M, Kupsch A, Ceballos-Baumann A, Ehret R, Polzer U, Klostermann F, Schwarz J, Fuchs G, Jost W, Albert A, Haag A, Hermsen A, Lohmüller K, Kuhn K, Wangemann M, Oertel WH, In Cooperation With the German Competence Network on Parkinson’s Disease.
    Clin Neuropharmacol; 2014; 37(4):116-22. PubMed ID: 24992083
    [Abstract] [Full Text] [Related]

  • 2. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.
    Razmy A, Lang AE, Shapiro CM.
    Arch Neurol; 2004 Jan; 61(1):97-102. PubMed ID: 14732626
    [Abstract] [Full Text] [Related]

  • 3. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A, Delwaide P, Jost W, Merello M, Williams A, Lamberti P, Aguilar M, Del Signore S, Cesaro P, Parkinson-Control Study Group.
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [Abstract] [Full Text] [Related]

  • 4. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, Tolosa E, Weintraub D.
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [Abstract] [Full Text] [Related]

  • 5. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group.
    Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J.
    JAMA; 2010 Jun; 287(4):455-63. PubMed ID: 11798367
    [Abstract] [Full Text] [Related]

  • 6. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort InvestigatorsDepartment of Neurology, University of Rochester, 1351 Mt Hope Ave, Ste 220, Rochester, NY 14620, USA. kevin.biglan@ctcc.rochester.edu.
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial.
    Högl B, Saletu M, Brandauer E, Glatzl S, Frauscher B, Seppi K, Ulmer H, Wenning G, Poewe W.
    Sleep; 2002 Dec; 25(8):905-9. PubMed ID: 12489899
    [Abstract] [Full Text] [Related]

  • 10. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial.
    Poewe W, Rascol O, Barone P, Hauser RA, Mizuno Y, Haaksma M, Salin L, Juhel N, Schapira AH, Pramipexole ER Studies Group.
    Neurology; 2011 Aug 23; 77(8):759-66. PubMed ID: 21832218
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
    Rascol O, Dubois B, Caldas AC, Senn S, Del Signore S, Lees A, Parkinson REGAIN Study Group.
    Mov Disord; 2006 Dec 23; 21(12):2110-5. PubMed ID: 17013922
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease.
    Paus S, Brecht HM, Köster J, Seeger G, Klockgether T, Wüllner U.
    Mov Disord; 2003 Jun 23; 18(6):659-67. PubMed ID: 12784269
    [Abstract] [Full Text] [Related]

  • 15. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A, Parkinson Study Group.
    Arch Neurol; 2004 Jul 23; 61(7):1044-53. PubMed ID: 15262734
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.